NCT04530227View on ClinicalTrials.gov

Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 25, 2020

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions
Early Stage Non-small Cell Lung Cancer
Interventions
DRUG

Biological: Camrelizumab

PD-1

DRUG

Pemetrexed

chemotherapy

DRUG

Nab-paclitaxel

chemotherapy

Trial Locations (1)

300060

RECRUITING

Tianjin Medical University Cancer Institute and Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER